Acta Neuropathologica

, Volume 87, Issue 5, pp 469–480 | Cite as

Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders

  • L. Buée
  • P. R. Hof
  • C. Bouras
  • A. Delacourte
  • D. P. Perl
  • J. H. Morrison
  • H. M. Fillit
Regular Paper

Abstract

Alterations of the cerebral microvasculature have been reported in aging and in neurodegenerative disorders such as Alzheimer's disease. However, the exact role of microvascular alterations in the pathogenesis of neurodegeneration remains unknown. In the present report, the cerebral cortex microvasculature was studied by immunohistochemistry using a monoclonal antibody against vascular heparan sulfate proteoglycan protein core in normal aging controls, Alzheimer's disease, Down syndrome, Guam amyotrophic lateral sclerosis/parkinsonian dementia complex, Pick's disease and dementia pugilistica. In all dementing illnesses, increased microvascular pathology was evident compared to normal controls. Decreased microvascular density and numerous atrophic vessels were the primary abnormalities observed in all dementing disorders. These microvascular abnormalities demonstrated regional and laminar selectivity, and were primarly found in layers III and V of frontal and temporal cortex. Quantitative analysis employing computer-assisted microscopy demonstrated that the decrease in microvascular density in Alzheimer's disease was statistically significant compared to age-matched controls. In addition, extracellular heparan sulfate proteoglycan deposits were observed which colocalized with thioflavine S-positive senile plaques in Alzheimer's disease, Down syndrome and selected Guam dementia cases. In some cases, heparan sulfate proteoglycan was seen in senile plaques that appeared to be diffuse or primitive plaques that stained weakly with thioflavine. Heparan sulfate proteoglycan-containing neurons were also observed in Alzheimer's disease, as well as in Down syndrome and Guam cases. Glial staining for heparan sulfate proteoglycan was never observed. Our data support previous observations that microvascular pathology is found in aging and in Alzheimer's disease. The changes in Alzheimer's disease exceed those found in normal aging controls. We also found microvascular pathology in all other dementing disorders studied. Our studies further demonstrated that the microvascular pathology displays regional and laminar patterns which parallel patterns of neuronal loss. Finally, we also found that heparan sulfate proteoglycan is present in senile plaques and neurons not only as previously reported in Alzheimer's disease, but also in Down syndrome and Guam cases. Heparan sulfate proteoglycan in senile plaques may be derived from either the degenerating microvasculature or from degenerating neurons. Further studies are necessary to determine the role of microvascular disease in the progression of Alzheimer's disease and other dementing disorders.

Key words

Microvasculature Dementia Heparan sulfate proteoglycan Alzheimer's disease Cerebral cortex 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebral Cortex 1: 103–116Google Scholar
  2. 2.
    Bell MA, Ball MJ (1981) Morphometric comparison of hippocampal microvasculature in ageing and demented people: diameters and densities. Acta Neuropathol (Berl) 53: 299–318Google Scholar
  3. 3.
    Bell MA, Ball MJ (1990) Neuritic plaques and vessels of visual cortex in aging and Alzheimer's dementia. Neurobiol Aging 11: 359–370Google Scholar
  4. 4.
    Buée L, Ding W, Anderson JP, Narindrasorasak S, Kisilevsky R, Greenberg B, Boyle NJ, Robakis N, Delacourte A, Fillit HM (1993) Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated through the N-terminal region of the A4 peptide. Brain Res 627: 199–204Google Scholar
  5. 5.
    Buée L, Ding W, Delacourte A, Fillit HM (1993) Binding of secreted human neuroblastoma proteoglycans to the Alzheimer amyloid A4 peptide. Brain Res 601: 154–163Google Scholar
  6. 6.
    Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921–923Google Scholar
  7. 7.
    Davies DC, Hardy JA (1988) Age and neurodegenerative disease related changes in the blood brain barrier deserve more through investigation. Neurobiol Aging 9: 46–48Google Scholar
  8. 8.
    Davies DC, Horwood N, Isaacs SL, Mann DMA (1992) The effect of age and Alzheimer's disease on pyramidal neuron density in the individual fields of the hippocampal formation. Acta Neuropathol 83: 510–517Google Scholar
  9. 9.
    Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 8: 1–21Google Scholar
  10. 10.
    Défossez A, Beauvillain JC, Delacourte A, Mazucca M (1988) Alzheimer's disease: new evidence for common epitopes between microtubule associated protein tau and paired helical filaments (PHF): demonstration at the electron microscopic level by a double immunogold labelling. Virchows Arch [A] 413: 141–145Google Scholar
  11. 11.
    Delacourte A, Flament S, Dibe EM, Hublau P, Sablonnière B, Hémon B, Scherrer V, Défossez A (1990) Pathological proteins tau 64 and 69 are specifically expressed in the somatodendritic domain of the degenerating cortical neurons during Alzheimer's disease: demonstration with a panel of antibodies against tau proteins. Acta Neuropathol 80: 111–117Google Scholar
  12. 12.
    Duvernoy HM (1988) The human hippocampus. Springer, New YorkGoogle Scholar
  13. 13.
    Duvernoy HM, Delon S, Vannson JL (1981) Cortical blood vessels of the human brain. Brain Res Bull 7: 519–579Google Scholar
  14. 14.
    Fillit HM, Buée L, Hof PR, Delacourte A, Morrison JH (1991) Cortical distribution of abnormal microvasculature and heparan sulfate proteoglycan positive plaques in Alzheimer's disease. Soc Neurosci [Abstr] 17: 692Google Scholar
  15. 15.
    Fischer VW, Siddiqui A, Yusufaly Y (1990) Altered angioarchitecture in selected areas of brains with Alzheimer's disease. Acta Neuropathol 79: 672–679Google Scholar
  16. 16.
    Fraser PE, Nguyen JT, Chin DT, Kirschner DA (1992) Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J Neurochem 59: 1531–1540Google Scholar
  17. 17.
    Frederickson RCA (1992) Astroglia in Alzheimer's disease. Neurobiol Aging 13: 239–253Google Scholar
  18. 18.
    Glenner GG, Wong CW (1984) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885–890Google Scholar
  19. 19.
    Hassler O (1965) Vascular changes in senile brains. Acta Neuropathol (Berl) 5: 40–53Google Scholar
  20. 20.
    Hof PR, Cox K, Morrison JH (1990) Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease. I. Superior frontal and inferior temporal cortex. J Comp Neurol 301: 44–54Google Scholar
  21. 21.
    Hof PR, Knabe R, Bovier P, Bouras C (1991) Neuropathological observations in a case of autism presenting with self-injury behavior. Acta Neuropathol 82: 321–326Google Scholar
  22. 22.
    Hof PR, Perl DP, Loerzel AJ, Morrison JH (1991) Neurofibrillary tangle distribution in the cerebral cortex of parkinsonism-dementia cases from Guam: differences with Alzheimer's disease. Brain Res 564: 306–313Google Scholar
  23. 23.
    Hof PR, Bouras C, Buée L, Delacourte A, Perl D, Morrison JH (1992) Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer's disease cases. Acta Neuropathol 85: 23–30Google Scholar
  24. 24.
    Hovingh P, Linker A (1974) The disaccharide repeating units of heparan sulfate. Carbohydr Res 37: 181–192Google Scholar
  25. 25.
    Jarrett JT, Lansbury PT Jr (1992) Amyloid fibril formation requires a chemically discriminating nucleation event: studies of an amyloidogenic sequence from the bacterial protein Osm B. Biochemistry 31: 12345–12352Google Scholar
  26. 26.
    Joachim CL, Selkoe DJ (1992) The seminal role of β-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis Assoc Disord 6: 7–34Google Scholar
  27. 27.
    Kalaria RN (1992) The blood-brain barrier and cerebral microcirculation in Alzheimer's disease. Cerebrovasc Brain Metab Rev 4: 226–260Google Scholar
  28. 28.
    Karthikeyan L, Maurel P, Rauch U, Margolis RK, Margolis RU (1992) Cloning of a major heparan sulfate proteoglycan from brain and identification as the rat form of glypican. Biochem Biophys Res Commun 188: 395–401Google Scholar
  29. 29.
    Kemeny E, Fillit HM, Damle SP, Mahabir R, Kefalides NA, Gregory JD, Antonovych T, Sabnis S, Zabriskie JB (1988) Monoclonal antibodies to heparan sulfate proteoglycan: development and application to the study of normal tissue and pathologic human kidney biopsies. Connect Tissue Res 18: 1–12Google Scholar
  30. 30.
    Kisilevsky R (1990) Heparan sulfate proteoglycans in amyloidogenesis: an epiphenomenon, a unique factor, or the tip of a more fundamental process? Lab Invest 63: 589–591Google Scholar
  31. 31.
    LaCoste M, White CL (1993) The role of cortical connectivity in Alzheimer's disease pathogenesis: a review and model system. Neurobiol Aging 14: 1–16Google Scholar
  32. 32.
    Lewis DA, Campbell MH, Terry RD, Morrison JH (1987) Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices. J Neurosci 7: 1799–1808Google Scholar
  33. 33.
    Mann DMA, Eaves NR, Marcyniuk B, Yates PO (1986) Quantitative changes in cerebral cortical microvasculature in ageing and dementia. Neurobiol Aging 7: 321–330Google Scholar
  34. 34.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939–944Google Scholar
  35. 35.
    Morrison JH (1993) Differential vulnerability, connectivity, and cell typology. Neurobiol Aging 14: 51–54Google Scholar
  36. 36.
    Narindrasorasak S, Lowery D, Gonzalez-DeWhitt P, Poorman RA, Greenberg B, Kisilevsky R (1991) High affinity interactions between the Alzheimer's β amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J Biol Chem 266: 12878–12883Google Scholar
  37. 37.
    Perlmutter LS, Chui HC (1990) Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 24: 677–686Google Scholar
  38. 38.
    Perlmutter LS, Chui HC, Saperia D, Athanikar J (1990) Microangiopathy and the colocalization of heparan sulfate proteoglycan with amyloid in senile plaques of Alzheimer's disease. Brain Res 508: 13–19Google Scholar
  39. 39.
    Perry G, Siedlak SL, Richey P, Kawai M, Cras P, Kalaria RN, Galloway PG, Scardina JM, Cordell B, Greenberg BD, Ledbetter SR, Gambetti P (1991) Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease. J Neurosci 11: 3679–3683Google Scholar
  40. 40.
    Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 12: 295–312Google Scholar
  41. 41.
    Ravens JR (1978) Vascular changes in the human senile brain. Adv Neurol 20: 487–501Google Scholar
  42. 42.
    Rogers J, Morrison JH (1985) Quantitative morphology and regional and laminar distribution of senile plaques in Alzheimer's disease. J Neurosci 5: 2801–2808Google Scholar
  43. 43.
    Scheibel AB, Duong T (1988) On the possible relationship of cortical microvascular pathology to blood brain barrier changes in Alzheimer's disease. Neurobiol Aging 9: 41–42Google Scholar
  44. 44.
    Scheibel AB, Duong T, Tomiyasu U (1987) Denervation microangiopathy in senile dementia, Alzheimer type. Alzheimer Dis Assoc Disord 1: 19–37Google Scholar
  45. 45.
    Snow AD, Wight TN (1989) Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol Aging 10: 481–497Google Scholar
  46. 46.
    Snow AD, Willmer JP, Kisilevsky R (1987) Sulfated glycosaminoglycans in Alzheimer's disease. Hum Pathol 18: 506–510Google Scholar
  47. 47.
    Stewart PA, Hayakawa K, Akers M, Vinters HV (1992) A morphometric study of the blood-brain barrier in Alzheimer's disease. Lab Invest 67: 734–742Google Scholar
  48. 48.
    Su JH, Cummings BJ, Cotman CW (1992) Localization of heparan sulfate glycosaminoglycan and proteoglycan protein core in aged brain and Alzheimer's disease. Neuroscience 51: 801–813Google Scholar
  49. 49.
    Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synaptic loss is the major correlate of cognitive impairment. Ann Neurol 30: 572–580Google Scholar
  50. 50.
    Tomlinson BE, Blessed S, Roth M (1970) Observations on the brains of demented old people. J Neurol Sci 11: 205–242Google Scholar
  51. 51.
    Vallet PG, Guntern R, Hof PR, Golaz J, Delacourte A, Robakis N, Bouras C (1992) A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathol 83: 170–178Google Scholar
  52. 52.
    Weisgraber KH, Rall SC Jr, Mahley RW, Milne RW, Marcel YL, Sparrow JT (1986) Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem 261: 2068–2076Google Scholar
  53. 53.
    Willingham MC, Rutherford AV (1984) The use of osmium-thiocarbohydrazide-osmium and ferrocyanide-reduced osmium methods to enhance membrane contrast and preservation in cultured cells. J Histochem Cytochem 32: 455–460Google Scholar
  54. 54.
    Wisniewski T, Frangione B (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135: 235–238Google Scholar
  55. 55.
    Wisniewski HM, Wegiel J, Wang KC, Lach B (1992) Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathol 84: 117–127Google Scholar
  56. 56.
    Zellweger H (1977) Down syndrome. Handbk Clin Neurol 31: 367–469Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • L. Buée
    • 1
    • 5
  • P. R. Hof
    • 1
    • 4
  • C. Bouras
    • 4
    • 6
  • A. Delacourte
    • 1
    • 5
  • D. P. Perl
    • 2
    • 4
  • J. H. Morrison
    • 1
    • 4
  • H. M. Fillit
    • 1
    • 3
    • 4
  1. 1.Department of Geriatrics and Adult DevelopmentThe Mount Sinai Medical CenterNew YorkUSA
  2. 2.Department of Pathology and PsychiatryThe Mount Sinai Medical CenterNew YorkUSA
  3. 3.Department of MedicineThe Mount Sinai Medical CenterNew YorkUSA
  4. 4.Fishberg Research Center for NeurobiologyThe Mount Sinai Medical CenterNew YorkUSA
  5. 5.Unité 156INSERMLille CédexFrance
  6. 6.Département de Psychiatrie, IUPG Bel-AirUniversité de GenèveGeneveSwitzerland

Personalised recommendations